183 related articles for article (PubMed ID: 32213316)
1. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria.
Kristoffersson AN; Rognås V; Brill MJE; Dishon-Benattar Y; Durante-Mangoni E; Daitch V; Skiada A; Lellouche J; Nutman A; Kotsaki A; Andini R; Eliakim-Raz N; Bitterman R; Antoniadou A; Karlsson MO; Theuretzbacher U; Leibovici L; Daikos GL; Mouton JW; Carmeli Y; Paul M; Friberg LE
Clin Microbiol Infect; 2020 Dec; 26(12):1644-1650. PubMed ID: 32213316
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.
Karnik ND; Sridharan K; Jadhav SP; Kadam PP; Naidu RK; Namjoshi RD; Gupta V; Gore MS; Surase PV; Mehta PR; Gogtay JA; Thatte UM; Gogtay NJ
Eur J Clin Pharmacol; 2013 Jul; 69(7):1429-36. PubMed ID: 23508665
[TBL] [Abstract][Full Text] [Related]
3. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.
Grégoire N; Mimoz O; Mégarbane B; Comets E; Chatelier D; Lasocki S; Gauzit R; Balayn D; Gobin P; Marchand S; Couet W
Antimicrob Agents Chemother; 2014 Dec; 58(12):7324-30. PubMed ID: 25267662
[TBL] [Abstract][Full Text] [Related]
4. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.
Mohamed AF; Karaiskos I; Plachouras D; Karvanen M; Pontikis K; Jansson B; Papadomichelakis E; Antoniadou A; Giamarellou H; Armaganidis A; Cars O; Friberg LE
Antimicrob Agents Chemother; 2012 Aug; 56(8):4241-9. PubMed ID: 22615285
[TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
Imberti R; Cusato M; Villani P; Carnevale L; Iotti GA; Langer M; Regazzi M
Chest; 2010 Dec; 138(6):1333-9. PubMed ID: 20558557
[TBL] [Abstract][Full Text] [Related]
6. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.
Plachouras D; Karvanen M; Friberg LE; Papadomichelakis E; Antoniadou A; Tsangaris I; Karaiskos I; Poulakou G; Kontopidou F; Armaganidis A; Cars O; Giamarellou H
Antimicrob Agents Chemother; 2009 Aug; 53(8):3430-6. PubMed ID: 19433570
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study.
Moni M; Sudhir AS; Dipu TS; Mohamed Z; Prabhu BP; Edathadathil F; Balachandran S; Singh SK; Prasanna P; Menon VP; Patel T; Patel P; Kaye KS; Menon VP
Int J Infect Dis; 2020 Nov; 100():497-506. PubMed ID: 32781161
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.
Boisson M; Jacobs M; Grégoire N; Gobin P; Marchand S; Couet W; Mimoz O
Antimicrob Agents Chemother; 2014 Dec; 58(12):7331-9. PubMed ID: 25267660
[TBL] [Abstract][Full Text] [Related]
11. Colistin in critically ill patients.
Boisson M; Gregoire N; Couet W; Mimoz O
Minerva Anestesiol; 2013 Feb; 79(2):200-8. PubMed ID: 23241733
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome.
Ram K; Sheikh S; Bhati RK; Tripathi CD; Suri JC; Meshram GG
Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):128-140. PubMed ID: 33245629
[TBL] [Abstract][Full Text] [Related]
13. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
[TBL] [Abstract][Full Text] [Related]
14. The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.
Zak-Doron Y; Dishon Benattar Y; Pfeffer I; Daikos GL; Skiada A; Antoniadou A; Durante-Mangoni E; Andini R; Cavezza G; Leibovici L; Yahav D; Eliakim-Raz N; Carmeli Y; Nutman A; Paul M;
Clin Infect Dis; 2018 Nov; 67(12):1815-1823. PubMed ID: 29718143
[TBL] [Abstract][Full Text] [Related]
15. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
[TBL] [Abstract][Full Text] [Related]
16. Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.
Menna P; Salvatorelli E; Mattei A; Cappiello D; Minotti G; Carassiti M
Chemotherapy; 2018; 63(1):35-38. PubMed ID: 29334366
[TBL] [Abstract][Full Text] [Related]
17. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analysis of colistin in burn patients.
Lee J; Han S; Jeon S; Hong T; Song W; Woo H; Yim DS
Antimicrob Agents Chemother; 2013 May; 57(5):2141-6. PubMed ID: 23439640
[TBL] [Abstract][Full Text] [Related]
19. Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.
Leuppi-Taegtmeyer AB; Decosterd L; Osthoff M; Mueller NJ; Buclin T; Corti N
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30478168
[TBL] [Abstract][Full Text] [Related]
20. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
